Vanda Pharmaceuticals Inc. (VNDA) Dividend History

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of proprietary drugs to treat central nervous system disorders, including schizophrenia, bipolar disorder, and other mental health conditions. The company is known for its innovative therapies and has a portfolio that includes products addressing underserved patient populations. Founded in 2000 and headquartered in Washington, D.C., Vanda emphasizes research and development to bring new treatment options to market.

2200 Pennsylvania Ave Nw, Washington, DC, 20037
Phone: 202-734-3400
Website: https://www.vandapharma.com

Dividend History

Vanda Pharmaceuticals Inc. currently does not pay dividends

Company News

  • Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight

    The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.

    GlobeNewswire Inc.
    Featured Companies: RVPH
  • Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?

    Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Zacks Investment Research
  • Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17. Check This Out: Alphabet, Toll Brothers And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Utilities shares rose by 1.5% on Wednesday. In trading on Wednesday, information technology shares fell by 1.1%.   Top Headline   U.S. Bancorp (NYSE: USB) reported upbeat first-quarter FY24 earnings on Wednesday. Revenue stood at $6.7 billion (-6.4% Y/Y), which aligns with the consensus. Adjusted earnings per share came in at 90 cents, beating the consensus of 88 cents.   Equities Trading UP   INVO Bioscience, Inc. (NASDAQ: INVO) shares shot up 218% to $2.4592 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024. Shares of Edible Garden AG Incorporated (NASDAQ: EDBL) got a boost, surging ...

    Benzinga
    Featured Companies: EDBL LGVN OTRK SAGE USB
  • Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

    Future Pak wants Vanda, but Vanda doesn't want Future Pak.

    The Motley Fool
Page data last updated 07/23/2025 03:08:11 UTC